16 Haziran 2021 Çarşamba

CureVac’s mRNA vaccine reaches an efficacy level of just 47 percent in a clinical trial.


By BY CARL ZIMMER from NYT Health The results were a blow to hopes that the vaccine could help meet the world’s urgent need. “This is pretty devastating” for the company, one expert said. https://ift.tt/2S4aRhB
zaman:
Etiketler: , , ,

Hiç yorum yok:

Yorum Gönder

Kaydol: Kayıt Yorumları (Atom)

Routine Childhood Vaccinations in the U.S. Slipped During the Pandemic

By BY BENJAMIN MUELLER AND JAN HOFFMAN from NYT Health Nationwide, the number of kindergartners with the required shots fell below the targ...